New generation adjuvants - From empiricism to rational design

Vaccine

Volumn 33, Issue S2, 2015, Pages B14-B20

  O'Hagan, Derek T ^a   Fox, Christopher B ^b  

^a Novartis Vaccines Cambridge   (United States)

^b IDRI   (United States)

Author keywords

Alum; Emulsion; Formulation; MPL; Vaccine adjuvant

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMMUNOLOGICAL ADJUVANT;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; EMPIRICISM; ISOLATION AND PURIFICATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; DRUG DISCOVERY; EMPIRICISM; HUMANS;

EID: 84929881519     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.088     Document Type: Review

References (41)

1. European Medicines Agency Fendrix: hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). EPAR summary for the public 2009.
2. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
3. Fox C.B., Moutaftsi M., Vedvick T.S., Coler R.N., Reed S.G. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine 2013, 31:5848-5855.
4. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008, 3:e3116.
5. ®, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against Pneumococcal disease in neonatal mice. Scand J Immunol 2009, 69:194-202.
6. Hailemichael Y., Dai Z., Jaffarzad N., Ye Y., Medina M.A., Huang X.-F., et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 2013, 19:465-472.
7. Hung I.F., Zhang A.J., To K.K., Chan J.F., Li C., Zhu H.-S., et al. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod, a double blind randomized controlled trial. Clin Infect Dis 2014, 10.1093/cid/ciu582.
8. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308:457-460.
9. fh cells and promote germinal center induction. Proc Natl Acad Sci 2012, 109:1080-1085.
10. Jain S., O'Hagan D.T., Singh M. The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011, 10:1731-1742.
11. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
12. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 2004, 93:273-282.
13. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res 2004, 21:2148-2152.
14. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 2006, 110:566-573.
15. Wendorf J., Chesko J., Kazzaz J., Ugozzoli M., Vajdy M., O'Hagan D.T., et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccines 2008, 4:44-49.
16. Wendorf J., Singh M., Chesko J., Kazzaz J., Soewanan E., Ugozzoli M., et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci 2006, 95:2738-2750.
17. Jain S., Malyala P., Pallaoro M., Giuliani M., Petersen H., O'Hagan D.T., et al. A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery. J Pharm Sci 2011, 100:646-654.
18. Ragupathi G., Damani P., Deng K., Adams M.M., Hang J., George C., et al. Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins. Vaccine 2010, 28:4260-4267.
19. Fernández-Tejada A., Chea E.K., George C., Pillarsetty N., Gardner J.R., Livingston P.O., et al. Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 2014, 6:635-643.
20. Fox C., Sivananthan S., Duthie M., Vergara J., Guderian J., Moon E., et al. A nanoliposome delivery system to synergistically trigger TLR4 and TLR7. J Nanobiotechnol 2014, 12:17.
21. Smirnov D., Schmidt J.J., Capecchi J.T., Wightman P.D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 2011, 29:5434-5442.
22. Wille-Reece U., Wu C.-Y., Flynn B.J., Kedl R.M., Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005, 174:7676-7683.
23. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29:9563-9572.
24. Calabro S., Tritto E., Pezzotti A., Taccone M., Muzzi A., Bertholet S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31:3363-3369.
25. Brito L.A., Chan M., Baudner B., Gallorini S., Santos G., O'Hagan D.T., et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 2011, 29:6262-6268.
26. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS PharmSciTech 2012, 13:498-506.
27. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30:2256.
28. Mata E., Salvador A., Igartua M., Hernández R.M., Pedraz J.L. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int 2013, 2013:19.
29. Sun B., Ji Z., Liao Y.-P., Wang M., Wang X., Dong J., et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano 2013, 7:10834-10849.
30. Li X., Aldayel A.M., Cui Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release 2014, 173:148-157.
31. Brito L.A., O'Hagan D.T. Designing and building the next generation of improved vaccine adjuvants. J Control Release 2014, 190:563-579.
32. Jafari H., Deshpande J.M., Sutter R.W., Bahl S., Verma H., Ahmad M., et al. Efficacy of inactivated poliovirus vaccine in India. Science 2014, 345:922-925.
33. Otten G.R., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005, 79:8189-8200.
34. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2:53ra74.
35. Idoko O.T., Owolabi O.A., Owiafe P.K., Moris P., Odutola A., Bollaerts A., et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis 2014, 94:564-578.
36. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
37. Brito L.A., Malyala P., O'Hagan D.T. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol 2013, 25:130-145.
38. O'Hagan D.T., Rappuoli R., De Gregorio E., Tsai T., Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011, 10:447-462.
39. Wiley S.R., Raman V.S., Desbien A., Bailor H.R., Bhardway R., Shakri A.R., et al. Targeting TLRs expands the antibody repetoire in response to a malaria vaccine. Sci Transl Med 2011, 3:93ra69.
40. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci 2008, 105:14265-14270.
41. Wu, et al. Sci Transl Med. 2014, 6:263ra160.